COMPUMED INC - CMPD STOCK NEWS

Techcyte and CompuMed collaborate to enhance digital manual review of organs for transplantation.

CompuMed, Inc. announces the purchase of CompuMed shares held by V.I. Capital Fund and David Pointer's resignation as a Director. The Fund owned 25.3% of the shares outstanding. CompuMed offered $2.00 per share for the shares being sold. Limited partners opted to retain some shares while the remaining shares are being purchased by CompuMed for a total cost of $724,336. The Corporation will retire the repurchased shares.

LOS ANGELES, CA / ACCESSWIRE / March 22, 2023 / CEO Lee Keddie of CompuMed has joined The Alliance National Innovation Leadership Council, which aims to foster collaboration in organ donation and transplantation. His leadership has significantly contributed to CompuMed's reputation as a top provider of clinical organ analysis, enhancing the efficiency of organ utilization and improving the lives of those involved in the process. Keddie's dedication to innovation in this field has been acknowledged through this prestigious appointment, which allows him to further influence organ transplantation practices and outcomes. CompuMed offers rapid diagnostic services through top specialists in telemedicine.

CompuMed, Inc. (OTC PINK:CMPD) reported fiscal 2022 fourth quarter revenue of $1.59 million, a 9.8% increase from last year, and annual revenue of $6.37 million, up 0.8%. However, net income decreased to $231,000 in Q4, down from $480,000 in the prior year. The company’s cash and accounts receivable position was $2.85 million, down 6.9% year-over-year. Despite customer attrition, CompuMed aims to accelerate adoption of new products. Adjusted for one-time costs, recurring net income stands at $726,000. Book value increased to $3.85 million, reflecting a 14.6% rise.

CompuMed, Inc. (OTC PINK:CMPD) reports its fiscal 2022 third-quarter results. Revenue rose 2.1% from the previous quarter but fell 7.4% year-over-year, having faced tough comparisons from record earnings last year. Operating income reached $136,000, a 155% increase from the previous quarter, yet down 46% from a year earlier. Cash and accounts receivable remained stable at $2,628,000. The company indicated ongoing investments in marketing may drive future sales growth.

CompuMed, Inc. (OTC PINK:CMPD) has implemented a 1-for-25 reverse stock split effective May 23, 2022, as approved by shareholders on March 15, 2022. This action consolidates 42,291,070 shares down to 1,691,643 shares, ensuring no change in par value. A temporary 'D' will be added to the ticker symbol, changing back to CMPD after 20 business days. Fractional shares will be settled in cash. The company will maintain share records through Computershare Trust Company in a book-entry format. Shareholders can request physical stock certificates if desired.

CompuMed, Inc. (OTC PINK:CMPD) reported Q2 fiscal 2022 results with revenue of $1.6 million, slightly down from $1.63 million in Q2 2021, but up 3.9% from the previous quarter. The company's operating income was $53,000, reflecting a significant decrease of 56% sequentially and 67% year-over-year, largely due to non-recurring legal costs. Cash and accounts receivable totaled $2.6 million, down 7% from Q1 2022. CompuMed has not utilized most of its $1 million share buyback authorization, indicating a cautious financial strategy.

CompuMed, Inc. (OTC PINK:CMPD) announced a 25:1 reverse stock split approved by stockholders in March 2022. The company is finalizing documents with FINRA and its transfer agent, ComputerShare, to implement this split, expected by mid-May 2022. CompuMed specializes in diagnostic telemedicine, offering services like telecardiology and teleradiology to provide affordable, real-time access to U.S. Board-Certified specialists. The company has been operational for over 26 years, servicing 1,000+ clinical settings worldwide.